# Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma

> **NCT07091227** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** AK112+oxaliplatin+capecitabine
- **DRUG:** oxaliplatin+capecitabine

## Key facts

- **NCT ID:** NCT07091227
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2026-07-20
- **Final completion:** 2029-07-20
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091227, "Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07091227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*